Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover
Abstract
A novel cytokine termed osteoprotegerin (OPG) that is also called osteoclastogenesis-inhibitory factor, which inhibits osteoclast maturation and activity, was recently isolated. In order to determine the influence of estrogen deficiency on the levels of circulating OPG in women, we studied the changes in the levels of circulating OPG in 10 Japanese women ages 25-49 (mean +/- SD, 34.0 +/- 6.9) years with endometriosis receiving gonadotropin-releasing hormone agonists (GnRH-a) therapy. We further analyzed whether the levels of circulating OPG have relations with the levels of the biomarkers of bone turnover or those of circulating mineral components in these patients during GnRH-a treatment. The patients were treated with a monthly injection of 3.75 mg leuprolide acetate depot for 6 months. In all patients, the concentrations of serum estradiol decreased after 6 months of GnRH-a treatment. The bone mineral density of the lumber spines in these patients significantly (P < 0.01) decreased (percentage change: mean +/- SD, -5.4 +/- 2.1%), while circulating OPG levels significantly (P < 0.01) increased after 6 months of treatment. The values of circulating OPG had significant correlations with those of urinary pyridinoline (r = 0.59, P < 0.01), urinary deoxypylridinoline (Dpd) (r = 0.46, P < 0.05), and serum alkaline phosphatase (r = 0.66, P < 0.01) but not with those of serum carboxy-terminal propeptide of type I procollagen during GnRH-a treatment. The values of circulating OPG also correlated significantly with those of serum calcium (Ca) and phosphorus (P) (r = 0.65 and 0.72, P < 0.01). Further analyses revealed that the percentage change in the value of circulating OPG had a significant correlation with that of urinary Dpd (r = 0.84, P < 0.01). These results suggest that circulating OPG levels rise against the increase in osteoblastic bone resorption and circulating Ca levels in the case of estrogen deficiency, possibly as a compensatory mechanism serving to limit circulating Ca levels and bone density.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
OPG levels generally increase after menopause and with GnRH agonist therapy, both low-estrogen conditions.
“There is general agreement that OPG levels increase after the menopause (373, 379 -381) and with GnRH agonist therapy (382), both conditions of low estrogen levels.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [382]
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works
Manolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,684 · see citing works
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440 · see citing works
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · see citing works
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O’Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 813 · see citing works
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · see citing works
Turner, R. T., Riggs, B. L., & Spelsberg, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 758 · see citing works
Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R. F., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 745 · see citing works
Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
Pacifici, R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110802 · Cited by 741 · see citing works
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · see citing works
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works
Browner, W. S., Lui, L., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 529 · see citing works
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · see citing works
Jono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K., & Nishizawà, Y. (2002) · Circulation · doi:10.1161/01.cir.0000031524.49139.29 · Cited by 483 · see citing works
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · see citing works
Ammann, P., Rizzoli, R., Bonjour, J. P., Bourrin, S., Meyer, J. M., Vassalli, P., & Garcia, I. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119333 · Cited by 310 · see citing works
Kimble, R. B., Srivastava, S., Ross, F. P., Matayoshi, A., & Pacifici, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28890 · Cited by 272 · see citing works
Pottratz, S. T., Bellido, T., Mocharla, H., Crabb, D. W., & Manolagas, S. C. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117100 · Cited by 269 · see citing works
Han, Z.-H., Palnitkar, S., Rao, D. S., Nelson, D. A., & PARFITT, A. M. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.4.498 · Cited by 251 · see citing works
Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status
Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., & Delmas, P. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7657 · Cited by 250 · see citing works
Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Kostenuik, P. J., & Shalhoub, V. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397807 · Cited by 224 · see citing works
Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200 · see citing works
Mice Lacking the Type I Interleukin-1 Receptor Do Not Lose Bone Mass after Ovariectomy
Lorenzo, J. A., Naprta, A., Rao, Y., Alander, C., Glaccum, M., Widmer, M., Gronowicz, G., Kalinowski, J., & Pilbeam, C. C. (1998) · Endocrinology · doi:10.1210/endo.139.6.6128 · Cited by 185 · see citing works
The Relative Contributions of Age and Years since Menopause to Postmenopausal Bone Loss
NORDIN, B. E. C., Need, A. G., Chatterton, B. E., Horowitz, M., & Morris, H. A. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-1-83 · Cited by 179 · see citing works
Physiology and Pharmacology of Bone
Mundy, G. R., & Martin, T. J. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77991-6 · Cited by 153 · see citing works
Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.
Tomoyasu, A., Goto, M., Fujise, N., Mochizuki, S.-I., Yasuda, H., Morinaga, T., Tsuda, E., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8443 · Cited by 83 · see citing works
Wallach, E. E., & Surrey, E. S. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57837-6 · Cited by 50 · see citing works
ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies
Chen, D., Sarikaya, N., Gunn, H., Martin, S. W., & Young, J. D. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.747 · Cited by 32 · see citing works
Combination of automatic HPLC‐RIA method for determination of estrone and estradiol in serum
Yasui, T., Yamada, M., Kinoshita, H., Uemura, H., Yoneda, N., Irahara, M., Aono, T., Sunahara, S., Mito, Y., Kurimoto, F., et al. (1999) · Journal of Clinical Laboratory Analysis · doi:10.1002/(sici)1098-2825(1999)13:6 · Cited by 28 · see citing works
Self-citationLupoli, G., Carlo, C. D., Nuzzo, V., Vitale, G., Russo, D., Palomba, S., & Nappi, C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03348007 · Cited by 13 · see citing works
The Role of GnRH Agonists Plus Add-Back Therapy in the Treatment of Endometriosis
Gargiulo, A., & Hornstein, M. D. (1997) · Seminars in Reproductive Medicine · doi:10.1055/s-2008-1068757 · Cited by 12 · see citing works
Predictive Value of Normal Hysterogram?
McDonough, P. G., Mol, B. W., Bossuyt, P. M., & van der Veen, F. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58176-x · Cited by 3 · see citing works
Flagged first, then by citations
5 of the 37 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works
The effect of bioactive glasses on bone marrow stromal cells differentiation
Bosetti, M., & Cannas, M. F. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2004.09.059 · Cited by 231 · see citing works
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215 · see citing works
Samelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 47 · see citing works
Abrahamsen, B., Hjelmborg, J., Kostenuik, P. J., Stilgren, L. S., Kyvik, K. O., Adamu, S., Brixen, K., & Langdahl, B. L. (2005) · Bone · doi:10.1016/j.bone.2004.12.015 · Cited by 45 · see citing works
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 37 · see citing works
Oostra, D., Lustberg, M. B., Reinbolt, R. E., Pan, X. J., Wesolowski, R., & Shapiro, C. L. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.028 · Cited by 18 · see citing works
- Authors
- Uemura, H., Yasui, T., Umino, Y., Niki, H., Takikawa, M., Saito, S., Furumoto, H., & Irahara, M.
- Affiliations
- Tokushima University (JP)
- Corresponding author
- Uemura, Hirokazu
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 33
- Issue
- 5
- Pages
- 860-866
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2171871304
- Cited by
- 7
- References
- 37
- Citations by year
- 2015: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Bone (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Keywords
- osteoprotegerin, GnRH agonist therapy, endometriosis, estrogen deficiency, bone turnover markers, bone mineral density, bone resorption, osteoclastogenesis inhibition, leuprolide, urinary pyridinoline, deoxypyridinoline, alkaline phosphatase, serum calcium, serum phosphorus
- MeSH terms
- Adult, Endometriosis, Female, Glycoproteins, Humans, Gonadotropin-Releasing Hormone, Middle Aged, Bone Density, Bone Remodeling, Leuprolide, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Statistics, Nonparametric, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
